Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical


Nhwa is conducting and funding this study to support NDA regulatory filing in China


Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China

CHESTERBROOK, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has enrolled the first patient in a Phase 3 trial for OLINVYK (oliceridine) injection, a novel IV analgesic approved in the U.S. by the Food and Drug Administration (FDA) for acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

“We are committed to delivering OLINVYK to patients and healthcare providers in need of alternative acute pain treatment options, both through our ongoing launch in the U.S. as well as our global partnerships,” said Carrie Bourdow, President and CEO of Trevena. “I am pleased that Nhwa has reached this important clinical development milestone, and we look forward to supporting their efforts to secure regulatory approval of OLINVYK in China.”

This is a randomized, double-blind, active-controlled study that will enroll approximately 160 patients following abdominal surgery. The study includes an OLINVYK arm and an IV morphine positive control arm. The primary efficacy endpoint is the proportion of responders to study medication based on their pain numeric rating scale (NRS) at the end of the randomized 24-hour treatment period. Safety and tolerability will be assessed by respiratory depression adverse events (AEs), sedation AEs, the use of rescue antiemetics, clinician- and patient-reported satisfaction, and other measures. The study was developed based on feedback from the Chinese National Medical Products Administration (NMPA). Following study completion, Nhwa expects to have sufficient clinical data, accompanied by Trevena’s existing clinical data, to submit OLINVYK for regulatory approval in China.

About OLINVYK® (oliceridine) injection

OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with FDA, the timing of FDA’s decision on the oliceridine NDA; available funding ; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 430-7576

PR & Media Contact:

Sasha Bennett
Associate Vice President
Clyde Group
[email protected]
(239) 248-3409 



Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

  • The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel

  • Topline results are expected during the fourth quarter of 2021

HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout. The Company’s COVID-19 program included over 100 patients across two Phase II studies in the U.S., Europe and Israel, and in compassionate use and expanded access programs in the U.S. and Israel. The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem’s PLX cells as a treatment for severe COVID-19 cases complicated by ARDS.

This decision comes in response to COVID-19’s evolution as a disease, as well as changes in the standard of care and a decline in the most severe cases. For the same reason, the Company will not pursue plans announced in December 2020 to expand Pluristem’s COVID-19 program to Mexico in collaboration with Innovare R&D. Pluristem expects to announce the topline results of the readout during the fourth quarter of 2021.

As part of the clinical readout, Pluristem will examine the safety and efficacy of PLX cells for treating ARDS, a condition associated with a number of illnesses in addition to COVID-19 including sepsis, smoke and toxic chemical inhalation, head and chest injuries, and pancreatitis. ARDS continues to pose a significant clinical challenge that affects over 200,000 Americans annually, roughly 10 percent of Intensive Care Unit patients and 23 percent of ventilated patients worldwide.

Pluristem continues to advance its product candidate pipeline – PLX-PAD and PLX-R18 – on a number of fronts. Pluristem’s PLX-PAD treatment exhibits the potential to stimulate tissue regeneration in response to muscle trauma and inflammation. PLX-PAD is currently in a Phase III multinational clinical trial testing the safety and efficacy of accelerating muscle regeneration following HIP fracture surgery. Additionally, Pluristem recently reported positive Phase I topline results from its evaluation of PLX-R18 cells to address incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT). The Company’s unique proprietary process and advanced development and manufacturing capabilities enable it to produce PLX cells at significant scale.                                 

About Pluristem

Pluristem is pushing the boundaries of science and engineering to reimagine pharmacological treatments and improve the standard of care. The Company’s cell therapies advance the field of regenerative medicine, with potentially groundbreaking applications for treating damaged muscle, hematology deficiencies, and inflammation. Pluristem sources its therapeutic cells from the placenta, an ethically accepted and potent source. Cells are easy to collect and do not require blood or tissue matching. Cells from one placenta can treat 20,000 patients. The Company’s manufacturing platform, the bioreactor, is a patented and validated state-of-the-art 3D cell expansion system, designed to mimic the human body. Pluristem’s method is uniquely accurate, cost-effective, and consistent batch-to-batch.

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the expected timing of the Phase II study clinical readout, the expected examination of the clinical readout in relating to treating ARDS for illnesses and causes in addition to COVID-19, the potential of its product candidates and its pipeline. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristem’s products may not be approved by regulatory agencies, Pluristem’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristem’s process; Pluristem’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristem’s patents may not be sufficient; Pluristem’s products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem’s reports filed from time to time with the Securities and Exchange Commission.

Contact:

Dana Rubin
Director of Investor Relations
+972-74-7107194
[email protected]



Summit Wireless to Host Virtual Roadshow on Thursday, July 15, 2021 at 11:30 a.m. Eastern Time

Summit Wireless to Host Virtual Roadshow on Thursday, July 15, 2021 at 11:30 a.m. Eastern Time

SAN JOSE, Calif.–(BUSINESS WIRE)–Summit Wireless Technologies, Inc. (NASDAQ: WISA), a leading provider of immersive wireless sound technology, will host a virtual roadshow on Thursday, July 15, 2021 at 11:30 a.m. Eastern Time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005290/en/

Brett Moyer, CEO of Summit Wireless, will present an overview of the business model and growth initiatives. The webinar will be accompanied by a presentation and followed by a question and answer session, which can be accessed via the webcast link or dial-in numbers below.

To access the webinar, please use the following information:

Date:

 

Thursday, July 15, 2021

Time:

 

11:30 a.m. Eastern time (8:30 a.m. Pacific time)

Dial-in:

 

1-877-423-9813

International Dial-in:

 

1-201-689-8573

Conference Code:

 

13721372

Webcast:

  http://public.viavid.com/index.php?id=145635

A telephone replay and transcript will be available approximately four hours after the call and will run through Sunday, August 15, 2021, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13721372. The replay can also be viewed through the webinar webcast link above.

About Summit Wireless Technologies, Inc.:

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless, formerly named Summit Semiconductor, Inc., is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information, please visit: www.summitwireless.com.

Investor Relations

Greg Falesnik or Brooks Hamilton

MZ Group – MZ North America

+1 (949) 546-6326

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Semiconductor Audio/Video Consumer Electronics Mobile/Wireless Technology

MEDIA:

Logo
Logo
Logo
Logo

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the “Novel Targets for Autoimmune Diseases” panel discussion at William Blair’s Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET.

A live webcast of the panel may be accessed at the “Events & Presentations” section of Kezar’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

Argot Partners

212-600-1902

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Oncology General Health Health Fitness & Nutrition Clinical Trials Other Health

MEDIA:

Brookfield Infrastructure Announces a Voluntary Sale Program

BROOKFIELD, NEWS, July 08, 2021 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN) and Brookfield Infrastructure Corporation (NYSE: BIPC; TSX: BIPC) (collectively “Brookfield Infrastructure”) today announced they are initiating a voluntary sale program (the “Program”) through which eligible holders of BIP limited partnership units and/or BIPC class A exchangeable subordinate voting shares (collectively the “Odd Lot Securities”) may conveniently sell their Odd Lot Securities. The program benefits securityholders who held fewer than 100 Odd Lot Securities, as of July 7, 2021, being the record date in respect of the Program, and want to sell their Odd Lot Securities without paying brokerage commissions, thereby avoiding having to incur fees that could represent a material percentage of their proceeds. Additionally, the Program should permit any interested holder of Odd Lot Securities on the record date (July 7, 2021) and who does not have a brokerage account the ability to sell their Odd Lot Securities without the cost and inconvenience of opening such an account.

Registered and beneficial holders of Odd Lot Securities as of the record date are able to participate. The program will run until September 30, 2021, unless otherwise extended, and will operate through the facilities of the New York Stock Exchange (“NYSE”) and Toronto Stock Exchange (“TSX”) in compliance with the NYSE and TSX policies of Odd Lot Selling and Purchase Arrangements.

Brookfield Infrastructure has arranged for Computershare Trust Company of Canada, Computershare Investor Services Pty Limited and Georgeson LLC (“Computershare”) to manage the Program. Questions regarding the Program should be directed to Computershare by calling toll free:

Computershare Trust Company of Canada:         (North America) +1 866 302 7102
(International) +1 514 982 7458

Computershare Investor Services Pty Limited (Australia) 1300 034 142

Georgeson LLC (US) + 1 855 641 0884

An information booklet with details about how to participate in the Program will be mailed to eligible holders on or about July 15, 2021, following which securityholders can tender their Odd Lot Securities online by visiting www.oddlotsaleprogram.com and using their unique system generated account code and control code on page 1 of the Letter of Transmittal.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction. Brookfield Infrastructure is not offering to purchase Odd Lot Securities from participants. Brookfield Infrastructure is not making any recommendation as it relates to holding or selling Odd Lot Securities, and is not making any representation as to the price which may be realized on the sale of Odd Lot Securities under the Program. Eligible securityholders may wish to obtain advice from their broker or financial advisor as to the advisability of participating in the Program. The tax consequences for each participant in the Program may vary. Brookfield Infrastructure and Computershare make no representations with respect to the tax consequences for a particular participant. It is recommended that each holder of Odd Lot Securities consult their personal tax advisor as to the consequences to them of a sale under the program. Participation in the program is voluntary.

Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across North and South America, Asia Pacific and Europe. We are focused on assets that have contracted and regulated revenues that generate predictable and stable cash flows. Investors can access its portfolio either through Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), a Bermuda-based limited partnership, or Brookfield Infrastructure Corporation (NYSE, TSX: BIPC), a Canadian corporation. Further information is available at www.brookfield.com/infrastructure.

Brookfield Infrastructure Partners is the flagship listed infrastructure company of Brookfield Asset Management, a global alternative asset manager with over US$600 billion of assets under management. For more information, go to www.brookfield.com.

For more information, please contact:

Media:

Claire Holland
Senior Vice President, Communications
Tel: (416) 369-8236
Email: [email protected]
Investors:

Kate White
Manager, Investor Relations
Tel: (416) 956-5183
Email: [email protected]

 



CAE and Volocopter to partner and create the global air taxi pilot workforce of tomorrow

PR Newswire

  • Ground-breaking training program to focus on safety and operationalization of eVTOL urban air mobility
  • Volocopter, urban air mobility pioneer, teams up with CAE, global leader in aviation training, to develop an electric vertical takeoff and landing (eVTOL) pilot training program in preparation for Volocopter’s first eVTOL aircraft upcoming entry-into-service
  • CAE commits to expanding its international training network to support Volocopter’s growth and global pilot training with a forecasted investment of up to US$40 million

MONTREAL, Canada and BRUCHSAL, Germany, July 8, 2021 /PRNewswire/ – (NYSE: CAE) (TSX: CAE) – CAE, a global leader in aviation training, and Volocopter, a leading pioneer of urban air mobility (UAM), announced today the signing of a strategic partnership, subject to definitive agreement, to develop, certify, and deploy an innovative pilot training program for electric vertical takeoff and landing (eVTOL) operations. A first in the industry, this eVTOL pilot training program will develop the pilot workforce of the future and ensure safe introduction of eVTOL operations globally by leveraging CAE’s advanced technologies such as Artificial Intelligence (AI), Virtual Reality (VR), Mixed Reality (MR), as well as data analytics and Volocopter’s leading understanding of requirements for integration into the UAM ecosystem.

UAM is an emerging part of the aviation industry focused on aerial connectivity in and around cities. Volocopter’s family of electric aircraft are designed to relieve today’s heavily fossil-fueled, inner-city traffic for both people (VoloCity, VoloConnect) and goods (VoloDrone) . The company’s first commercial eVTOL aircraft, the VoloCity, is well into its certification program with the European Union Aviation Safety Agency (EASA) and is positioned to launch first services in time for the 2024 Olympics in Paris. Through existing agreements and partnerships with global leaders, such as Daimler, Aéroports de Paris, Microsoft Azure, and now CAE, Volocopter plans to launch its services in a number of cities globally within the next five years. Volocopter is committed to seeking certification with the highest global safety standards for aircraft and operations.

CAE commits to expanding its worldwide training network with a forecasted investment of up to US$40 million to meet Volocopter’s projected pilot demand in the early years of operation. CAE will be deploying training equipment and instructors in lockstep with Volocopter’s growth. As part of the agreement, Volocopter will purchase a simulator from CAE to be used in its pilot training program certification. CAE will create new, student-centric courseware, specifically designed for the pilots of the future as Volocopter’s courseware provider and will also offer pilot trainees customized resources that enable faster, more efficient pilot training.

“As we scale our UAM services in cities around the world, specific pilot training and qualification for our Volocopters will be an important element. We are proud to be partnering with CAE, who have a track record in developing best-in-class, innovative pilot training solutions for new aircraft programs. It will greatly benefit Volocopter’s entry-into-service timeline and scale,” says Florian Reuter, CEO of Volocopter. “We are excited about CAE’s endorsement and look forward to collaborate as partners focused on combining future-oriented technologies to ensure aviation safety.”

“As a high-technology company and the industry leader in pilot training, we continuously look at providing solutions that make the world a safer place,” said Nick Leontidis, CAE’s Group President, Civil Aviation Training Solutions. “We are committed to supporting Volocopter’s inspiring vision and we look forward to leading in the design of UAM pilot training that prioritizes safety of operations through our data-driven solutions, world-class pilot training experience, and longstanding relationships with civil aviation authorities across the globe.”

As outlined in CAE’s Advanced Air Mobility white-paper published this month (link), advanced air mobility will create an additional surge in the demand for pilots, with an estimated 60,000 pilots needed within the first decade of operation. Volocopter and CAE will work closely together to obtain regulatory approval for their pilot training program of the future.

About Volocopter

Volocopter is building the world’s first sustainable and scalable urban air mobility business to bring affordable air taxi services to megacities worldwide. With the VoloCity, the company is developing the first fully electric “eVTOL” aircraft in certification to transport passengers safely and quietly within cities. Volocopter leads and cooperates with partners in infrastructure, operations, and air traffic management to build the ecosystem necessary to ‘Bring Urban Air Mobility to Life’.

In 2011, Volocopter performed the first-ever crewed flight of a purely electric multicopter and has since showcased numerous public flights with its full-scale aircraft. The most notable have been the public test flights at Singapore’sMarina Bay in October 2019 and the world’s first autonomous eVTOL flight in Dubai 2017. Volocopter is also developing products for the logistics space with their heavy-lift cargo variant, the VoloDrone. 

Founded in 2011 by Stephan Wolf and Alexander Zosel, Volocopter has 400 employees in offices in Bruchsal, Munich, and Singapore. The company has raised a total of €322 million in equity. Volocopter’s investors include Daimler, Geely, DB Schenker, BlackRock, and Intel Capital amongst others. 
Find out more at: www.volocopter.com 

About CAE

CAE is a high technology company, at the leading edge of digital immersion, providing solutions to make the world a safer place. Backed by a record of more than 70 years of industry firsts, we continue to reimagine the customer experience and revolutionize training and operational support solutions in civil aviation, defence and security, and healthcare. We are the partner of choice to customers worldwide who operate in complex, high-stakes and largely regulated environments, where successful outcomes are critical. As testament to our customers’ ongoing needs for our solutions, over 60 percent of CAE’s revenue is recurring in nature. We have the broadest global presence in our industry, with approximately 10,000 employees, 160 sites, and training locations in over 35 countries. www.cae.com

Follow us on Twitter: CAE_Inc
Facebook: www.facebook.com/cae.inc
LinkedIn: www.linkedin.com/company/cae

Hashtags: #CAE; #CAEpilot

Note to editors: High-resolution photos are available at https://www.cae.com/multimedia-centre/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cae-and-volocopter-to-partner-and-create-the-global-air-taxi-pilot-workforce-of-tomorrow-301327632.html

SOURCE CAE INC.

Gryphon Digital Mining Announces Major Purchase of 7,200 S19J Pro Antminers

Gryphon entered into an agreement for the purchase of 7,200 S19J Pro Miners, for a combined total of 720 PH of hashing power, representing a major milestone in the company’s goal to be an industry-leading Bitcoin miner with a zero carbon footprint.

PR Newswire

NEW YORK, July 8, 2021 /PRNewswire/ — Gryphon Digital Mining (“Gryphon”, “Gryphon Mining” or the “Company”), which recently announced that it has entered into a merger agreement with Sphere 3D (Nasdaq: ANY), today announced it has entered into an agreement to purchase 7,200 Antminer S19J Pro mining machines from Bitmain Technologies Limited (“Bitmain”) for an aggregate purchase price of $48 million.

The agreement relating to the purchase of the S19J Pro miners represents a significant step forward in Gryphon Digital Mining’s strategic initiative to increase its Bitcoin hash rate, while simultaneously maintaining a zero carbon footprint. The S19J Pro is the latest model from Bitmain that is scheduled for release this summer. The new miner boasts a maximum hash rate of 100 TH/s combined, with an industry-leading energy efficiency ratio of 29.5 J/TH, and an expected life cycle of over five years.

Bitmain is scheduled to deliver 600 miners on a monthly basis to Gryphon, with the first delivery starting next month in August 2021. The entry into this purchase agreement will provide Gryphon with a significant total hash rate, and the company’s fleet of high-efficiency miners will be a part of the only cryptocurrency mining operating with a 100% renewable energy supply.

“We are happy to provide Gryphon with Bitmain’s latest next-gen miners, the Antminer S19j Pro. Gryphon’s zero carbon footprint demonstrates their long-term initiative with being involved in the digital currency mining sector. We are confident that Gryphon will continue to expand their business and provide reliable and low-cost mining. We look forward to our continued cooperation with them in the future as they expand their operations,” said Irene Gao, Antminer Sales Director of NCSA Region, Bitmain.

This purchase agreement is considerably important as Gryphon Digital Mining demonstrates its ability to work with key industry partners, and its focus on achieving the goal of becoming a market leader by providing zero carbon emitting, reliable, low-cost mining.

In addition to this Bitmain order and its growing hashing power, Gryphon has partnered with one of the largest digital currency data centers in the world to access electricity costs as low as $0.013/kWh, with access to liquid immersion technology shown to extend the life of mining machines by at least 20 percent.

To learn more about Gryphon, please visit https://gryphondigitalmining.com/.


About Gryphon Digital Mining


Gryphon Digital Mining
 is a Bitcoin mining operation with zero carbon footprint. Gryphon’s long-term strategy is to be the first vertically integrated crypto miner with a wholly-owned, 100 percent renewable energy supply. Gryphon provides reliable, low-cost hydro-electric powered mining with plans to expand to other renewables such as nuclear, wind, and solar power to lower mining’s impact on the environment. Gryphon Digital Mining has entered into a merger agreement with Sphere 3D (Nasdaq: ANY) through which Gryphon shareholders are expected to become large shareholders of Sphere 3D, which is expected to maintain its Nasdaq listing.

Important Additional Information Will be Filed with the SEC

In connection with the proposed transaction between Sphere 3D and Gryphon, the parties intend to file a registration statement on Form F-4 (the “Registration Statement”), which will include a preliminary proxy statement of Sphere 3D and a prospectus in connection with the merger. The definitive proxy statement/prospectus and other relevant documents will be mailed to shareholders of Sphere 3D as of a record date to be established for voting on the merger. Stockholders of Sphere 3D and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus, and amendments thereto, the definitive proxy statement/prospectus in connection with Sphere 3D’s solicitation of proxies for the special meeting to be held to approve the merger, and other documents filed with the SEC by Sphere 3D and Gryphon, because these documents will contain important information about Sphere 3D, Gryphon, and the merger. Stockholders will also be able to obtain copies of the Registration Statement and the proxy statement/prospectus, without charge, by directing a request to: 895 Don Mills Road, Bldg. 2, Suite 900, Toronto, Ontario, M3C1W3, Canada. These documents, once available, and Sphere 3Ds annual and other reports and proxy statements filed with the SEC can also be obtained, without charge, at the SEC’s internet site (http://www.sec.gov).

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed merger or an offer to sell, the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. This press release is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful.

Participants in the Solicitation

Sphere 3D, and its directors, executive officers, other members of management and employees and Gryphon, and its directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Sphere 3D in connection with the proposed merger. A list of the names of those directors and executive officers and a description of their interests in Sphere 3D will be included in the proxy statement/prospectus for the proposed merger and will be available at www.sec.gov free of charge. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed merger when available.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, as amended. These forward-looking statements are typically identified by terms and phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” “will,” or similar expressions.

These forward-looking statements include references to assumptions and relate to the future prospects, developments, and business strategies of Gryphon and Sphere 3D. These forward-looking statements are largely based on the current expectations and projections about future events and trends that are expected to affect the financial condition, results of operations, business strategy, and short-term and long-term business operations and objectives of Gryphon and Sphere 3D. Forward-looking statements contained in this press release include, but are not limited to, statements concerning the following: (i) the expectation that Gryphon will be able to raise the capital necessary to finance the purchase of the bitcoin miners from Bitmain, (ii) the expectation that Gryphon will and Bitmain will satisfy the conditions and requirements of the purchase agreement with Bitmain such that Gryphon will receive delivery of the bitcoin miners from Bitmain, (iii) the anticipated benefits of the merger transaction with Sphere 3D; (iv) the current and future build out and acquisition plans of Gryphon and Sphere 3D; (v) expected mining capacity in the future; (vi) the proposed merger and other contemplated transactions (including statements relating to satisfaction of the conditions to and consummation of the proposed merger, the expected ownership of the combined company and the ability of the combined company to raise additional capital to complete bitcoin mining programs and opportunities relating to or resulting from the merger),  (vii) the nature, potential approval and commercial success of the combined company and its planned bitcoin mining operations; and (viii) other statements about the business plans, business strategies and operations of the combined company in the future.

Forward-looking statements are subject to a number of risks, uncertainties and assumptions. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include but are not limited to: (i) the inability of Gryphon to successfully raise the capital necessary to pay the purchase price for the bitcoin miners to Bitmain, (ii) the occurrence of any event, change, or other circumstances that could give rise to the termination of the merger transaction or delay in the closing of the merger transaction, including the failure of Sphere 3D’s stockholders to adopt the merger agreement and approve related issuances of its securities; (iii) the ability to recognize the anticipated objectives and benefits, including any tax benefits, of the proposed merger transaction; (iv) changes in applicable laws, regulations or permits affecting Gryphon and Sphere 3D’s operations or the industries in which each operate, including regulation of cryptocurrency; (v) risks related to failure to obtain adequate financing on a timely basis and on acceptable terms with regard to growth strategies or operations; (v) fluctuations in the market pricing of cryptocurrencies; (vii) loss of public confidence in cryptocurrencies; (viii) the potential of cybercrime, money laundering, malware infections and phishing, and the costs associated with such issues; (ix) the potential of cryptocurrency market manipulation; (x) the economics of mining cryptocurrency, including as to variables or factors affecting the cost, efficiency and profitability of mining; (xi) the availability, delivery schedule and cost of equipment necessary to grow the business and operations of Gryphon, including mining equipment, (xii) the possibility that the combined company may be adversely affected by other economic, business or competitive factors, including factors affecting the industries in which they operate or upon which they rely and are dependent; (xiii) an inability to expand successfully to  new facilities, mine other cryptocurrencies or otherwise expand the business; (xiv) changes in tax regulations applicable to Gryphon or Sphere 3D or their respective assets; (xv) any potential litigation involving either or both of Gryphon or Sphere 3D; (xvi) costs and expenses relating to cryptocurrency transaction fees and fluctuation in cryptocurrency transaction fees; (xvii) other risks and uncertainties related to the business plan, business strategy, acquisition strategy and buildout strategy of Gryphon and Sphere 3D; (xviii) risks related to Sphere 3D’ ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed merger pending closing; (xix) the cash balances of the combined company following the closing of the merger; (xx) the ability of Sphere 3D to remain listed on the Nasdaq Capital Market; (xxi) the risk that as a result of adjustments to the exchange ratio, Sphere 3D shareholders or Gryphon stockholders could own more or less of the combined company than is currently anticipated; (xxii) the potential economic fallout resulting from the COVID-19 outbreak; and (xxiii) the risks, uncertainties, and other factors detailed from time to time in Sphere 3D’s reports filed or furnished with the U.S. Securities and Exchange Commission. The actual results, performance, or achievements of Gryphon and Sphere 3D could differ materially from the results expressed in, or implied by, any forward-looking statements.

In addition, the forward-looking statements included in this press release represent Sphere 3D and Gryphon’s views as of the date hereof. Sphere 3D and Gryphon anticipate that subsequent events and developments will cause their respective views to change. However, while Sphere 3D and Gryphon may elect to update these forward-looking statements at some point in the future, Sphere 3D and Gryphon specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Sphere 3D’ or Gryphon’s views as of any date subsequent to the date hereof.

COMPANY CONTACT: [email protected]

MEDIA CONTACT: [email protected]

INVESTOR CONTACT:

Name: Rob Chang

Company: Gryphon Digital Mining

Phone Number: (877) MINE-ESG

(877) 646-3374

Email: [email protected]

 

 

Cision View original content:https://www.prnewswire.com/news-releases/gryphon-digital-mining-announces-major-purchase-of-7-200-s19j-pro-antminers-301327511.html

SOURCE Gryphon Digital Mining

BNY Mellon to Bolster Digital Solutions Capabilities with Planned Acquisition of Fund Management Technology Leader Milestone Group

PR Newswire

NEW YORK, July 8, 2021 /PRNewswire/ — The Bank of New York Mellon Corporation (“BNY Mellon”) today announced it has entered into a definitive agreement to acquire Milestone Group (“Milestone”), a leading provider of fund management technology. The deal comes just over a year after the two companies formed an alliance to create a suite of oversight and contingent net asset value (NAV) services for asset managers and asset owners seeking independent oversight and backup NAV capabilities. Terms of the acquisition were not publicly disclosed. Closing of the transaction is subject to customary conditions and approvals and is expected to occur in the second half of 2021.

“This transaction with Milestone is the latest demonstration of BNY Mellon’s commitment to support clients across the investment lifecycle and provide clients with open and flexible digital solutions that enable them to optimize, scale and grow their businesses,” said Roman Regelman, BNY Mellon’s CEO of Asset Servicing and Head of Digital. “We gain both industry-leading technology as well as the expertise that Milestone is known for globally. This is a significant step in our continuous evolution — blending leading edge technologies and services to deliver greater efficiency and value for our clients.”

Milestone’s pControl™ platform is widely recognized as an industry leader in fund and investment automation. By acquiring Milestone, BNY Mellon will advance the digitization and automation of core accounting and asset services, delivering increased accuracy and timeliness. It also will expand BNY Mellon’s digital offerings and core capabilities — adding OCIO services, cash allocation and fair value control solutions to the existing suite of NAV solutions.

The benefits to BNY Mellon’s clients will be numerous, including: 

  • Bolstered resiliency and transparency packaged in a seamless digital experience
  • Access to a leading platform and an array of digital solutions; all supported by experienced leadership and BNY Mellon’s established reputation as a long-standing trusted provider
  • The flexibility to choose from existing and new end-to-end solutions that add operating model choices, strategic product capabilities and industry connectivity

“We’re excited about becoming part of BNY Mellon and are committed to making this a seamless experience for all of our clients. We are proud of the reputation we have built at Milestone over the last two decades and the industry innovation we’ve delivered for asset managers, fund administrators and asset allocators including pension funds, life companies, fiduciaries and multi-asset product providers,” said Geoff Hodge, Executive Chairman of Milestone Group. “We have made great progress collaborating with BNY Mellon to deliver best-in-class solutions, and the synergies we will be able to achieve together to provide new and exciting solutions to the industry is a thrilling opportunity.”

For additional information, please visit BNY Mellon’s website.

About BNY Mellon

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. Whether providing financial services for institutions, corporations or individual investors, BNY Mellon delivers informed investment and wealth management and investment services in 35 countries. As of March 31, 2021, BNY Mellon had $41.7 trillion in assets under custody and/or administration, and $2.2 trillion in assets under management. BNY Mellon can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute or restructure investments. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). Additional information is available on www.bnymellon.com. Follow us on Twitter @BNYMellon or visit our newsroom at www.bnymellon.com/newsroom for the latest company news.

Contact: 

Paul Patella

BNY Mellon 
[email protected] 
+1 212 635 1378 

 

Cision View original content:https://www.prnewswire.com/news-releases/bny-mellon-to-bolster-digital-solutions-capabilities-with-planned-acquisition-of-fund-management-technology-leader-milestone-group-301327635.html

SOURCE BNY Mellon

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021

PR Newswire

LEXINGTON, Mass., July 8, 2021 /PRNewswire/ — LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled “Delivery and Durability of Genetic Medicines” at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.

About LogicBio Therapeutics 
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company’s first platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell’s natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company’s second platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

Investor Contact: 
Laurence Watts
Gilmartin Group
(619) 916-7620
[email protected]

Media Contacts:

Adam Daley

Berry & Company Public Relations
W: 212-253-8881
C: 614-580-2048
[email protected]

Jenna Urban

Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021-301327648.html

SOURCE LogicBio Therapeutics, Inc.

AI is the Transformative Force Revolutionizing Future Human Development Over the Next 40 Years, Says Baidu CEO Robin Li at WAIC 2021

PR Newswire

  • Baidu’s chief says technological advancements can spur the gradual restoration of humanity to become a low-carbon society
  • The importance of AI extends beyond economic growth, its true contribution towards society is the creation of social value
  • Baidu to expand its Apollo Go robotaxi ride-hailing services and roll out new species robo-vehicle in the next two to three years

SHANGHAI, July 8, 2021 /PRNewswire/ —  Robin Li, the Co-founder and CEO of Baidu, Inc. (NASDAQ:BIDU and HKEX:9888), today said that AI will undoubtedly become the transformative force revolutionizing future human development over the next 40 years during his keynote speech at the annual World Artificial Intelligence Conference (WAIC). Li highlighted that the intelligent transformation ushered by AI towards industries and societies is to ultimately fulfil the needs of people, proclaiming that technology is meaningful only if it serves humanity through the creation of more value and contributing towards society.

In light of this year’s WAIC theme, “Intelligent Connectivity, Inspirational Cities”, Li contended that the value of AI to human society extends far beyond economic growth, stating his belief that the social value of AI deeply correlates with the human desire for a better life. The annual event was held at the Shanghai World Expo Exhibition and Convention Center, aiming to promote the exchange of global AI innovation and build a world-class industrial cluster of AI.  

“Baidu’s approach towards AI technology has always revolved around delivering equitable outcomes by making technology more accessible, providing freedom and possibilities for all,” Li said.

Some parts of the world are facing an aging population issue; China’s elderly population is slated to exceed 300 million residents, creating a new challenge that will impact the country’s economic growth, social security, public services and more, Li said in his speech. In this regard, AI solutions are proven to be highly dependable in providing health monitoring, rehabilitation care, emergency aid, emotional support and meal or transport assistance for elders.

Natural language processing (NLP), multi-modal interactive AI assistant and computer vision capabilities have enabled Xiaodu – Baidu’s signature smart display product – to provide elders with immediate assistance and virtual companionship around the clock, improving their quality of life greatly while remotely reassuring family members of their healthy and safety. 

In Li’s view, the application of AI technology is reshaping the landscape of industries to become the transformative force revolutionizing future human development over the next 40 years. Baidu’s multi-faceted AI solutions are collectively addressing the socio-economic and environmental challenges faced by the modern world, to ultimately accomplish better living and sustain high-quality development for all of mankind.

“Baidu has been preparing for many years to embrace this digital revolution. Our advanced autonomous driving technology has positioned us as a global leader of the smart transportation industry. Not long ago, we launched Apollo Moon, the newest generation of Baidu’s robotaxis that aims to create a fully autonomous ride-hailing service that will be more affordable than existing vehicle-for-hire platforms. Baidu plans to expand its robotaxi ride-hailing services across 30 cities in China in two to three years to serve a wider range of users. Baidu is also rapidly developing a new intelligent vehicle, and we estimate that everyone will be able to experience the arrival of new species, ‘robo-vehicles’, in two to three years,” he added.   

Li also spoke about the impactful role Baidu Apollo has been playing as many Chinese cities continue to construct world-class intelligent traffic systems. Smart transportation solutions have been shown to facilitate a 15% improvement in traffic efficiency, which translates into a 2.4% GDP growth, demonstrating considerable commercial value to society.

This increase in efficiency can also reduce carbon emissions and curb the negative impact of climate change. By implementing smart transportation systems through intelligent vehicles and roads, Baidu is revolutionizing the industry by promoting safer and greener travel, fostering a lower carbon lifestyle and creating immense social value.

Owing to the rapid technological advancement in recent years, AI can empower the gradual restoration of humanity to become a low-carbon society. In line with its vision to facilitate the low carbon transition in society for long-term sustainable development, Baidu has announced its goal to achieve carbon neutrality in its operations by 2030. After 2030, Baidu will collaborate with its ecological partners to work towards becoming carbon negative, joining hands to further China’s pledge to become carbon neutral by 2060 and to limit the global warming to 1.5 degrees Celsius.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation. Baidu is traded on the NASDAQ Global Select Market under the symbol “BIDU”, and on the main board of the Hong Kong Stock Exchange under the stock code “9888”. Currently, one ADS represents eight Class A ordinary shares.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-is-the-transformative-force-revolutionizing-future-human-development-over-the-next-40-years-says-baidu-ceo-robin-li-at-waic-2021-301327838.html

SOURCE Baidu, Inc.